Open AccessCase Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis
Author(s) -
Pamela Konecny,
Christopher J. Weatherall,
Suman Adhikari,
Johan Duflou,
Veli Marjoniemi,
Carel Pretorius,
Brett McWhinney
Publication year - 2018
Publication title -
american journal of tropical medicine and hygiene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.015
H-Index - 151
eISSN - 1476-1645
pISSN - 0002-9637
DOI - 10.4269/ajtmh.18-0387
Subject(s) - ivermectin , strongyloidiasis , strongyloides , pharmacokinetics , strongyloides stercoralis , antiparasitic agent , medicine , helminthiasis , biology , immunology , virology , pathology , pharmacology , helminths , veterinary medicine
Parenteral ivermectin treatment of disseminated strongyloidiasis and hyperinfection is increasing, although not licensed in humans and with limited pharmacokinetic data available. Plasma and postmortem tissue analysis in an human immunodeficiency virus (HIV)/hepatitis C virus-positive man with disseminated strongyloidiasis suggests loading subcutaneous ivermectin doses are required, from which the central nervous system is protected.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom